Procalcitonin detection in human plasma specimens using a fast version of proximity extension assay

PLoS One. 2023 Feb 16;18(2):e0281157. doi: 10.1371/journal.pone.0281157. eCollection 2023.

Abstract

An exciting trend in clinical diagnostics is the development of easy-to-use, minimally invasive assays for screening and prevention of disease at the point of care. Proximity Extension Assay (PEA), an homogeneous, dual-recognition immunoassay, has proven to be sensitive, specific and convenient for detection or quantitation of one or multiple analytes in human plasma. In this paper, the PEA principle was applied to the detection of procalcitonin (PCT), a widely used biomarker for the identification of bacterial infection. A simple, short PEA protocol, with an assay time suitable for point-of-care diagnostics, is presented here as a proof of concept. Pairs of oligonucleotides and monoclonal antibodies were selected to generate tools specifically adapted to the development of an efficient PEA for PCT detection. The assay time was reduced by more than 13-fold compared to published versions of PEA, without significantly affecting assay performance. It was also demonstrated that T4 DNA polymerase could advantageously be replaced by other polymerases having strong 3'>5' exonuclease activity. The sensitivity of this improved assay was determined to be about 0.1 ng/mL of PCT in plasma specimen. The potential use of such an assay in an integrated system for the low-plex detection of biomarkers in human specimen at the point of care was discussed.

MeSH terms

  • Antibodies, Monoclonal
  • Bacterial Infections*
  • Biomarkers
  • Humans
  • Immunoassay / methods
  • Procalcitonin*

Substances

  • Procalcitonin
  • Antibodies, Monoclonal
  • Biomarkers

Grants and funding

The main part of the authors are permanent employees of BioMerieux SA. Additionally, work for the study was done in laboratories and offices with equipment and consumables provided by BioMerieux. Two authors are external service providers (Assystem Care company) paid by bioMerieux for temporary missions. The specific roles of these authors are articulated in the ‘author contributions’ section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.